KRAS and colorectal cancer: The mutations in BRAF and KRAS oncogenes which have been found in approximately 10–20% and 35–42% of sporadic colorectal cancers respectively [246,247,248], has been shown to contribute to the up-regulation of COX-2 [249,250].